{"id":"W2557786287","doi":"10.1093/neuonc/now212.100","title":"ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Rash; Clinical endpoint; Cohort; Oncology; Surgery; Clinical trial; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003704152,0.0002841052,0.0007645766,0.0002165316,0.00005096239,0.000004103497,0.0002476657,0.0002317515,0.00005531488],"category_scores_gemma":[0.0002818493,0.0001532458,0.0002279722,0.0003862436,0.0004574549,0.00009021227,0.000057285,0.0002653178,0.000004122655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004284724,"about_ca_system_score_gemma":0.000469872,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001613461,"about_ca_topic_score_gemma":0.0002833419,"domain_scores_codex":[0.9973399,0.0003788895,0.0009888432,0.0004741217,0.000446503,0.000371757],"domain_scores_gemma":[0.9978037,0.0005256992,0.0007506917,0.0005878124,0.0002390839,0.00009302606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7231946,0.004010451,0.01011889,0.000022432,0.0001788977,0.00001487786,0.0007218288,0.000001912379,0.1426796,0.000003412762,0.000291765,0.1187613],"study_design_scores_gemma":[0.6651527,0.04695207,0.1726023,0.0003670894,0.0001229858,0.00001715867,0.00005770197,0.00007902625,0.1066597,0.000004440932,0.007768318,0.0002164793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946029,0.0000639894,0.00004267877,0.001124266,0.0007858595,0.002775784,0.0002326994,0.00002259148,0.0003492635],"genre_scores_gemma":[0.9987854,0.0002181682,0.0002007238,0.0004795809,0.0000949126,0.0001013049,0.00001619632,0.00004040829,0.00006325806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1624834,"threshold_uncertainty_score":0.6249182,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01553732485719488,"score_gpt":0.3030960722070924,"score_spread":0.2875587473498975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}